Literature DB >> 33508434

SIRT3 as a potential therapeutic target for heart failure.

Jie Chen1, Shiqi Chen1, Bingxia Zhang1, Junwei Liu2.   

Abstract

Heart failure causes significant morbidity and mortality worldwide. The underlying mechanisms and pathological changes associated with heart failure are exceptionally complex. Despite recent advances in heart failure research, treatment outcomes remain poor. The sirtuin family member sirtuin-3 (SIRT3) is involved in several key biological processes, including ATP production, catabolism, and reactive oxygen species detoxification. In addition to its role in metabolism, SIRT3 regulates cell death and survival and has been implicated in the pathogenesis of cardiovascular diseases. Emerging evidence also shows that SIRT3 can protect cardiomyocytes from hypertrophy, ischemia-reperfusion injury, cardiac fibrosis, and impaired angiogenesis. In this review article, we summarize the recent advances in SIRT3 research and discuss the role of SIRT3 in heart failure. We also discuss the potential use of SIRT3 as a therapeutic target in heart failure.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac remodeling; Heart failure; SIRT3; Sirtuins

Mesh:

Substances:

Year:  2021        PMID: 33508434     DOI: 10.1016/j.phrs.2021.105432

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

1.  Profiling sirtuin activity using Copper-free click chemistry.

Authors:  Alyson M Curry; Ian Cohen; Song Zheng; Jessica Wohlfahrt; Dawanna S White; Dickson Donu; Yana Cen
Journal:  Bioorg Chem       Date:  2021-10-08       Impact factor: 5.275

Review 2.  The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis.

Authors:  Dijana Stojanovic; Valentina Mitic; Miodrag Stojanovic; Jelena Milenkovic; Aleksandra Ignjatovic; Maja Milojkovic
Journal:  Front Cardiovasc Med       Date:  2022-05-31

Review 3.  The roles and mechanisms of epigenetic regulation in pathological myocardial remodeling.

Authors:  Kun Zhao; Yukang Mao; Yansong Li; Chuanxi Yang; Kai Wang; Jing Zhang
Journal:  Front Cardiovasc Med       Date:  2022-08-26

Review 4.  Cardiac Acetylation in Metabolic Diseases.

Authors:  Emilie Dubois-Deruy; Yara El Masri; Annie Turkieh; Philippe Amouyel; Florence Pinet; Jean-Sébastien Annicotte
Journal:  Biomedicines       Date:  2022-07-29

5.  Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF).

Authors:  María Valero-Muñoz; Eng Leng Saw; Ryan M Hekman; Benjamin C Blum; Zaynab Hourani; Henk Granzier; Andrew Emili; Flora Sam
Journal:  Front Cardiovasc Med       Date:  2022-08-25

Review 6.  The Mitochondrial Unfolded Protein Response: A Novel Protective Pathway Targeting Cardiomyocytes.

Authors:  Jinfeng Liu; Xinyong He; Sicheng Zheng; Aisong Zhu; Junyan Wang
Journal:  Oxid Med Cell Longev       Date:  2022-09-21       Impact factor: 7.310

7.  Therapeutic hypothermia alleviates myocardial ischaemia-reperfusion injury by inhibiting inflammation and fibrosis via the mediation of the SIRT3/NLRP3 signalling pathway.

Authors:  Jing Zhang; Yimei Lu; Peng Yu; Zhangwang Li; Yang Liu; Jun Zhang; Xiaoyi Tang; Shuchun Yu
Journal:  J Cell Mol Med       Date:  2022-08-29       Impact factor: 5.295

8.  Sirt3 Protects Against Thoracic Aortic Dissection Formation by Reducing Reactive Oxygen Species, Vascular Inflammation, and Apoptosis of Smooth Muscle Cells.

Authors:  Lin Qiu; Shaolei Yi; Tingting Yu; Yan Hao
Journal:  Front Cardiovasc Med       Date:  2021-05-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.